Back to Journals » Vascular Health and Risk Management » Volume 14

Critical limb ischemia: current challenges and future prospects

Authors Uccioli L, Meloni M, Izzo V, Giurato L, Merolla S, Gandini R

Received 25 July 2017

Accepted for publication 5 December 2017

Published 26 April 2018 Volume 2018:14 Pages 63—74


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Konstantinos Tziomalos

Luigi Uccioli,1 Marco Meloni,1 Valentina Izzo,1 Laura Giurato,1 Stefano Merolla,2 Roberto Gandini2

1Department of Systems Medicine, 2Department of Interventional Radiology, Università di Tor Vergata Roma, Rome, Italy

Abstract: Critical limb ischemia (CLI) is considered the most severe pattern of peripheral artery disease. It is defined by the presence of chronic ischemic rest pain, ulceration or gangrene attributable to the occlusion of peripheral arterial vessels. It is associated with a high risk of major amputation, cardiovascular events and death. In this review, we presented a complete overview about physiopathology, diagnosis and holistic management of CLI. Revascularization is the first-line treatment, but several challenging cases are not treatable by conventional techniques. Unconventional techniques for the treatment of complex below-the-knee arterial disease are described. Furthermore, the state-of-the-art on gene and cell therapy for the treatment of no-option patients is reported.

Keywords: peripheral arterial disease, critical limb ischemia, medical therapy, revascularization, cell therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]